In today’s briefing:
- AIMD: Deep Dive into AI-Powered Smell in Semi Fabs and Robotics After Recent Partnerships
- What’s New(s) in Amsterdam – 10 April (Fagron)
- Max Healthcare (MAXHEALTH IN): Multi-Pronged Expansion Strategy Augurs Well for Sustainable Growth

AIMD: Deep Dive into AI-Powered Smell in Semi Fabs and Robotics After Recent Partnerships
- AI Nose for healthcare, industrials, and robotics. Ainos is digitizing smell with AI Nose to capture airborne chemical signatures, using AI-powered processes to immediately classify and identify scents in any environment.
- Initially focused on healthcare, Ainos is developing a women’s health test, Ainos Flora with AI Nose, in addition to an elderly care project with Japanese partners to assist caregivers in monitoring seniors.
- Ainos recently entered partnerships with ugo and ASE, expanding AI Nose development to robotics and industrial applications.
What’s New(s) in Amsterdam – 10 April (Fagron)
- organic revenue CAGR at CER: high single digit to low double digits
- REBITDA margin: approx. 21.0% by 2027, with a progressive increase through 2030
- Operating Cash Flow conversion: ≥70%
Max Healthcare (MAXHEALTH IN): Multi-Pronged Expansion Strategy Augurs Well for Sustainable Growth
- Max Healthcare Institute (MAXHEALT IN) completed the acquisition of Jaypee Healthcare in last November, thereby adding 700 beds. Jaypee added INR1,120M revenue with an operating EBITDA of INR230M in Q3FY25.
- Max is setting up ~500 bedded hospital at Thane, Maharashtra on an asset-light built-to-suit basis. The proposed construction of hospital premises is expected to be completed by 2028.
- Current expansion plan indicates significant capacity ramp-up (20%+) in FY26, and majority of which will come by Q1, thereby generating scope for revenue realization for most part of the year.
